Morgan Stanley Downgrades enGene Therapeutics to Underweight

Benzinga Newsdesk www.benzinga.com Negative 92.1%

Neg 92.1% Neu 0% Pos 0%

Morgan Stanley analyst Judah Frommer downgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Underweight.

Comments

No comments yet. Be the first!